Vaccine and biologics industry leaders gather in Pune for IMAPAC’s 12th Annual Vaccines World Summit and Biologics Festival India

The last decade has marked an era of growth in India’s healthcare sector and the next promises exciting times for it. There is no other health intervention as simple, powerful and cost-effective as a ‘vaccine.’ Currently, more than two thirds of the total volume of the vaccines manufactured is exported, while the rest is utilised domestically. According to a new report by IMARC titled “Indian Vaccine Market Report and Forecast 2020-2025,” the Indian vaccine market reached a value of Rs 94 billion in 2019.

As India shifts from being a low-cost generic vaccine supplier into an R&D power house, local vaccine manufacturers seek to fast track and gain greater access to the latest vaccine technologies through global partnerships. In recent years, there is a significant rise in global partnerships where international and local vaccine players come together to learn and complement one another’s capabilities.

Currently, in its 11th year, the Vaccine World Summit 2022 (co-located with Biologics Festival India) in Pune, India from 5th to 6th May, 2022, provided an opportunity for the “whole vaccine manufacturing value chain” to explore partnerships at various stages of the vaccine lifecycle, beginning with the fundamental research, and extending through to the licensing and production stages.

More than 530 participants from over 150 vaccines and biologics organisations came together to participate in the in-person conference.

The conference presents thought leaders the opportunity to exchange views on how industry players can link arms to build a better future as well as scale up the next wave of innovation. With networking opportunities, presentations of case studies and discussions, the Vaccines and Biologics conference is the place to be! From market landscape to regulatory strategy, from recent invention of COVID-19 monoclonal antibodies to pandemic preparedness, this event aims to capture a holistic view of the issues challenging the industry.

The 2022 conference programme features industry visionary presentations from DCVMN, Bristol Myers Squibb, Zydus Cadila Healthcare, Bharat Biotech International, Intas Pharma, PATH, Serum Institute of India, Cadila Pharma, Bill and Melinda Gates Foundation, Sanofi Pasteur and many more. Technology providers such as MR Sanghavi and Co, Pelican Biothermal, Marken, Ami Polymer, Sartorius Stedim Biotech Gmbh, Datwyler Pharma Packaging, West Pharma Services, Pall Life Sciences, EMBALL’ISO were also there to showcase their latest solutions.

Alongside the conferences, IMAPAC’s India Biologics and Vaccines Outstanding Industry Awards (BVOIA) 2022 facilitated vaccine R&D and biologics manufacturing excellence at enhanced speed, reduced cost and superior quality. Featuring top vaccine and biomanufacturing leaders in the industry, along with the latest advances in technologies and the best practices in R&D and manufacturing, the India Biologics and Vaccines Outstanding Achievement Award 2022 applauded the extraordinary leaders and trend-setters of today and inspired the innovators of tomorrow.